SCHEMBL5361474

SCHEMBL5361474

Cc1cc(C)c(C=C2C(=O)Nc3ccc(C(=O)Nc4ccccc4)cc32)[nH]1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLK2 Q86UE8 1/20 0.70
PAK4 O96013 1/20 0.69
KDR P35968 6/20 0.64
PDGFRB P09619 4/20 0.64
PDGFRA P16234 3/20 0.64
RET P07949 10/20 0.62
FLT3 P36888 4/20 0.61
ALK Q9UM73 4/20 0.61
FGFR1 P11362 3/20 0.61
CSF1R P07333 2/20 0.61
SRC P12931 2/20 0.61
FLT1 P17948 2/20 0.61
FGFR3 P22607 2/20 0.61
MAPK1 P28482 2/20 0.61
FLT4 P35916 2/20 0.61
PDPK1 O15530 2/20 0.61
AURKB Q96GD4 2/20 0.61
ABL1 P00519 2/20 0.61
NTRK1 P04629 2/20 0.61
MEN1 O00255 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5368286 0.85 PAK4 (0.69) TLK2PAK4KDRPDGFRBPDGFRA
SCHEMBL14519103 0.85 TLK2 (0.82) TLK2PAK4KDRPDGFRBPDGFRA
SCHEMBL16568378 0.85 TLK2 (0.82) TLK2PAK4KDRPDGFRBPDGFRA
SCHEMBL5362637 0.82 TLK2 (0.77) TLK2PAK4KDRPDGFRBPDGFRA
SCHEMBL13712838 0.81 GSK3B (0.55) TLK2KDRPDGFRBRETFGFR1
SCHEMBL5366152 0.81 GSK3B (0.51) TLK2PAK4KDRPDGFRBRET
SCHEMBL30685915 0.81 KDR (0.70) TLK2PAK4KDRPDGFRBPDGFRA
SCHEMBL17480334 0.80 TLK2 (0.68) TLK2PAK4KDRPDGFRBPDGFRA
SCHEMBL5366834 0.80 GSK3B (0.52) TLK2PAK4KDRPDGFRBFGFR1
SCHEMBL5368790 0.79 TLK2 (0.66) TLK2PAK4KDRPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK TLK2 48/4885PAK4 682/4885KDR 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.